HAc40 is a novel microbiome modulator, effective on atopic dermatitis in children: data from two pilot vehicle-controlled trials
J Eur Acad Dermatol Venereol
.
2021 Nov;35(11):e767-e768.
doi: 10.1111/jdv.17431.
Epub 2021 Jun 18.
Authors
R Sacchetti
1
,
G Gregori
1
,
E Moggio
2
,
L Gobbo
3
,
L Bonzano
4
,
G Pellacani
5
Affiliations
1
Local Health Unit, Department of Primary Care Piacenza, Medicina di Gruppo Pediatrica Piccolo Daino, Piacenza, Italy.
2
Dermatology Unit. Bergamo, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy.
3
Medical And Scientific Marketing department. Novate Milanese, Aileens Pharma, Monza-Brianza, Italy.
4
Division of Dermatology, Allergology Service, Policlinico University Hospital of Modena, Modena, Italy.
5
Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Dermatology, University of La Sapienza, Rome, Italy.
PMID:
34062015
DOI:
10.1111/jdv.17431
No abstract available
Publication types
Controlled Clinical Trial
Letter
MeSH terms
Child
Dermatitis, Atopic* / drug therapy
Eczema*
Humans
Microbiota*